The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001240336
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
12/09/2026
Date registered
Help: Date registered
13/10/2026
Date last updated
Help: Date last updated
13/10/2026
Date data sharing statement initially provided
Help: Data sharing statement date
13/10/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Phase 2a, Placebo Controlled Single-Center Study to Evaluate the Safety and Tolerability of Multiple Ascending Doses of study drug MMB-003 in Participants with Ulcerative Colitis (UC).
Scientific title
A Phase 2a, Double Blind, Placebo Controlled Single-Center Study to Evaluate the Safety and Tolerability of multiple Ascending Doses of MMB-003 in Participants with Ulcerative Colitis (UC)
Additional trial identifiers [1] 318411 0
Nil known
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Ulcerative Colitis 343559 0
Condition category
Condition code
Inflammatory and Immune System 339668 339668 0 0
Other inflammatory or immune system disorders
Oral and Gastrointestinal 339669 339669 0 0
Inflammatory bowel disease

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
MMB-003 is a recombinant live biotherapeutic product consisting of a genetically modified strain of Escherichia coli Nissle 1917, known as EcN::ttr. MMB-003 will be administered orally as a capsule containing micro encapsulated beads of live EcN::ttr.

Part 2 visits and timelines:
Screening (V1) onsite - Day -21 to Day -2 prior to dosing - to review eligibility
Start cohort 1 - enrol 4 participants, patients will receive low dose 1 capsule 106 CFU/capsule. 3 participants will receive MMB-003 and 1 will receive placebo (randomisation (3:1)
Cohort 1 safety data review will take place prior to escalation (min 7 days)
Start cohort 2 - enrol 4 new participants, patients will receive low dose 1 capsule 108 CFU/capsule. 3 participants will receive MMB-003 and 1 will receive placebo (randomisation (3:1)
Cohort 2 safety data review will take place prior to escalation (min 7 days)
Start cohort 3 - enrol 4 new participants, patients will receive low dose 1 capsule 1010 CFU/capsule. 3 participants will receive MMB-003 and 1 will receive placebo (randomisation (3:1)
An optional, additional cohort of 4 participants may be enrolled to clarify dose selection if deemed necessary. Unknown dose at this stage.

Dosing will occur Day 0 (v2b) onsite, Day 7 (V4) onsite, Day 14 (V5) onsite, Day21 (V6) by delegated nursing staff

MMB-003 capsules will be supplied at three dose levels along with matching placebo capsules containing microencapsulated beads made of non-active excipient ingredients (no bacteria).
MMB-003 1x10^6 CFU/capsule
MMB-003 1x10^8 CFU/capsule
MMB-003 1x10^10 CFU/capsule
Placebo (blank bead) 0 CFU/capsule

UC participants will be enrolled in multi-dose cohorts. Participants will receive a single oral dose of either MMB-003 or placebo, administered every 7 days, on Day 0, Day 7 (±2 days), Day 14 (±2 days) and Day 21 (±2 days), for a total of 4 doses. There will be 3 cohorts of 4 participants, with an optional cohort of an additional 4 participants. In each cohort, 3 will receive active and 1 will receive placebo. In Part 2, sentinel dosing will be used (1:1:2) in each cohort for their first dose. Participants will be randomized into the dose cohort and will not follow any specific order between the active and placebo treatment. The placebo could be assigned to any of the 4 participants in the cohort. The first participant will receive either MMB-003 or placebo on Day 0 (relative to that first participant’s dose), followed by a minimum 7-day gap to ensure adequate evaluation of safety and tolerability prior to administering the same dose of MMB-003 or placebo to the second sentinel participant, followed by dose administration of the same dose of MMB-003 or placebo for the remaining participants. A minimum 7-day gap between sentinels (first and second participants) will be applied. After a minimum of 7 days of safety review from the two sentinels, the third and fourth participants can be dosed on the same day. The dose escalation may be adjusted based on safety and tolerability data from Part 1, and safety and tolerability data from the preceding cohort.

Part 2 Cohorts: treatment duration will be 21 days – dosing every 7 days.

Supervised dosing at clinic visits with medication review at each visit.
Intervention code [1] 335310 0
Treatment: Drugs
Description of the comparator or control
UC participants will be enrolled in multi-dose cohorts. Participants will receive a single oral dose of either MMB-003 or placebo, administered every 7 days, on Day 0, Day 7 (±2 days), Day 14 (±2 days) and Day 21 (±2 days), for a total of 4 doses. Placebo capsules containing microencapsulated beads made of non-active excipient ingredients (no bacteria).

Part 2 visits and timelines:
Screening (V1) onsite - Day -21 to Day -2 prior to dosing - to review eligibility
Start cohort 1 - enrol 4 participants, patients will receive low dose 1 capsule 1x10^6/capsule. 3 participants will receive MMB-003 and 1 will receive placebo (randomisation (3:1)
Cohort 1 safety data review will take place prior to escalation (min 7 days)
Start cohort 2 - enrol 4 new participants, patients will receive low dose 1 capsule 1x10^8 CFU/capsule. 3 participants will receive MMB-003 and 1 will receive placebo (randomisation (3:1)
Cohort 2 safety data review will take place prior to escalation (min 7 days)
Start cohort 3 - enrol 4 new participants, patients will receive low dose 1 capsule 1x10^10 CFU/capsule. 3 participants will receive MMB-003 and 1 will receive placebo (randomisation (3:1)
An optional, additional cohort of 4 participants may be enrolled to clarify dose selection if deemed necessary. Unknown dose at this stage.

Dosing will occur Day 0 (v2b) onsite, Day 7 (V4) onsite, Day 14 (V5) onsite, Day21 (V6) by delegated nursing staff

Supervised dosing in clinic with e-diary to capture patient reported outcomes only. Patient will bring the bottles at every visit to conduct drug accountability.

Control group
Placebo

Outcomes
Primary outcome [1] 346849 0
Part 2 (MAD) – To evaluate the safety of multiple ascending doses of MMB-003 in UC participants.
Timepoint [1] 346849 0
Safety lab tests collected Vitals collected Screening (Visit 1) – provided no later than 24 hours after Visit 1; Baseline (Visit 2a) Day 0 – provided within 24 hours before receiving dose Follow-Up (Visits 4, 5, 6) Days 7, 14 & 21 ±2 days, and EOS (Visit 8) Day 49 ±4 days, and unscheduled (as required).
Primary outcome [2] 346958 0
Part 2 (MAD) – To evaluate the tolerability of multiple ascending doses of MMB-003 in UC participants.
Timepoint [2] 346958 0
All AEs reported during the Treatment Period, will be categorized using Common Terminology Criteria for Adverse Events (CTCAE) and evaluated to assess the need for participant, cohort, and/or study termination in accordance with pre-specified criteria from screening. Treatment period to include Day 0 (v2b) onsite, Day 7 (V4) onsite, Day 14 (V5) onsite, Day21 (V6)
Primary outcome [3] 346959 0
Part 2 (MAD) – To evaluate the safety of multiple ascending doses of MMB-003 in UC participants.
Timepoint [3] 346959 0
Vitals collected Screening (Visit 1) – provided no later than 24 hours after Visit 1; Baseline (Visit 2a) Day 0 – provided within 24 hours before receiving dose Follow-Up (Visits 4, 5, 6) Days 7, 14 & 21 ±2 days, and EOS (Visit 8) Day 49 ±4 days, and unscheduled (as required).
Secondary outcome [1] 467827 0
To characterize the pharmacokinetics (stool shedding) of MMB-003 in UC participants.
Timepoint [1] 467827 0
Screening (Visit 1) – provided no later than 24 hours after Visit 1; Baseline (Visit 2a) Day 0 – provided within 24 hours before receiving dose Follow-Up (Visits 4, 5, 6) Days 7, 14 & 21 ±2 days, and EOS (Visit 8) Day 49 ±4 days.
Secondary outcome [2] 467828 0
To assess the impact of MMB-003 on the gut microbiome composition (diversity) in stool samples collected from UC participants.
Timepoint [2] 467828 0
Screening (Visit 1) – provided no later than 24 hours after Visit 1; Baseline (Visit 2a) Day 0 – provided within 24 hours before receiving dose Follow-Up (Visits 4, 5, 6) Days 7, 14 & 21 ±2 days, and EOS (Visit 8) Day 49 ±4 days.
Secondary outcome [3] 467829 0
To assess the impact of MMB-003 on metabolites in plasma, urine, and stool collected from UC participants.
Timepoint [3] 467829 0
Stool - Screening, Baseline Pre-Dose, Follow-Up (Visits 4, 5, 6), End of Study (V8) and unscheduled (if required); Plasma – Screening (V1), Baseline Pre-Dose, Follow-Up (Visits 4, 5, 6), End of Study (V8); Urine – Screening (V1), Baseline Pre-Dose, Follow-Up (Visits 4, 5, 6), End of Study (V8) Part 2 MAD (UC) participants Stool - Screening, baseline pre-dose, follow-up visit 4, 5 and 6, End of study (v8) and unscheduled (if required) Plasma - Screening, follow-up visit 4, 5 and 6, End of study (v8) urine - Screening, baseline pre-dose, follow-up visit 4, 5 and 6, End of study (v8)
Secondary outcome [4] 467830 0
To assess the impact of MMB-003 on gene expression in peripheral blood from UC participants.
Timepoint [4] 467830 0
Screening (Visit 1), Follow Up/Dosing (Visits 4, 5, 6) Day 7, 14, 21 ±2 days and EOS (Visit 8) Day 49 ±4 days.
Secondary outcome [5] 467831 0
To assess the impact of MMB-003 on fecal calprotectin in UC participants.
Timepoint [5] 467831 0
Screening (Visit 1) – provided no later than 24 hours after Visit 1; Baseline (Visit 2a) Day 0 – provided within 24 hours before receiving dose Follow-Up (Visits 4, 5, 6) Days 7, 14 & 21 ±2 days, and EOS (Visit 8) Day 49 ±4 days
Secondary outcome [6] 468364 0
To assess the impact of MMB-003 on the function in metagenomics in stool samples collected from UC participants.
Timepoint [6] 468364 0
Screening (Visit 1) – provided no later than 24 hours after Visit 1; Baseline (Visit 2a) Day 0 – provided within 24 hours before receiving dose Follow-Up (Visits 4, 5, 6) Days 7, 14 & 21 ±2 days, and EOS (Visit 8) Day 49 ±4 days.

Eligibility
Key inclusion criteria
1. In the opinion of the Investigator, the participant is capable of understanding and complying with protocol requirements.
2. The participant signs and dates an informed consent form.
3. Male or female participants aged 18-65 years.
4. Body Mass Index (BMI) between 18.0 and 30.0 kg/m2.
5. Diagnosis of ulcerative colitis for at least 6 months prior to screening.
6. Stable dose of standard-of-care UC medications, including advanced therapies and immunomodulators initiated (on stable dose) greater than or equal to 4 weeks prior to screening.
7. Willingness and ability to provide informed consent and comply with study procedures and assessments.
8. Agree to avoid any major changes from the participant’s typical dietary practices (e.g. start a new diet such as vegan, vegetarian, carnivore, etc.) for the duration of the study.
9. Women either of non-childbearing potential or using a contraceptive (e.g. hormonal pill, IUD) during study and for 60 days following each administration of the investigational drug.
10.All participants must agree to use a double physical barrier (e.g. male condom and a diaphragm) and abstain from unprotected anal sex and/or analingus for 60 days following each administration of the investigational drug (per OGTR DIR 221 Licence Condition 28). This is to prevent any potential transmission of the GMO to a non-participant.
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
History of toxic megacolon, colectomy, Crohn’s disease or indeterminate colitis.
History of any non-IBD diarrheal illness (e.g. Clostridioides difficile infection, celiac disease, parasitic infection) within 3 months of screening.
Severe active ulcerative colitis (e.g., Partial Mayo Score >6): active disease with Partial Mayo Score less than or equal to 6 permitted.
Use of corticosteroids within 1 month prior to screening.
Use of newly initiated therapies including immunomodulators within 4 weeks prior to screening. Participants receiving stable immunomodulator therapy greater than 4 weeks are permitted.
Use of antibiotics within 1 month prior to screening.
Use of probiotics/prebiotics within 2 weeks prior to screening (consumption of food products such as yogurt, kefir, kombucha and herbal teas is permissible).
Use of agents that can alter gut transit time (e.g., laxatives, anti-diarrheal medications, and diabetic and weight loss medications)
Recipient of Fecal Microbial Transplantation (FMT) or other fecal derived therapy, within 6 months prior to screening.
Any acute or chronic medical condition that, in the opinion of the Investigator, would make participation unsafe.
Planned pregnancy before the end of the trial, pregnancy or lactation.
Positive screening test for human immunodeficiency virus (HIV) or hepatitis panel.
Addiction to alcohol or illicit drugs (cannabis-derived products less than 3 times a week excepted whether illicit or not) within the last year.
Positive urine drug screen at Screening, other than for cannabis-derived products consistent with the permitted use describe above, unless another positive result is attributable to a documented permitted medication and is considered not clinically significant by the Investigator.
Participant does not have a mobile device (Android or iOS).

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
The randomization schedule linking kit codes to treatment assignment (active vs. placebo) will be accessible only to designated overseas Melius employees who are not otherwise involved in study conduct and who labels the product. All study team members at the clinical site will remain blind to treatment assignment for the duration of the study.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
The randomization will be generated by the Integrated Medical Development portal.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
The sample size chosen of 4 participants in each cohort (3 active: 1 placebo) is considered to be sufficient for evaluation of safety and tolerability of each cohort. The sample size was not based on statistical power considerations.
Safety:
Safety analyses will focus on AEs. For each dose level, the number and percentage of participants reporting AEs will be tabulated by preferred term, system organ class categorized by maximum severity and relationship to study therapy for each dose level.
AEs will be presented in listings, and summarized in tables.
AEs will be categorized using CTCAE v5.0
Individual results of laboratory tests (hematology and chemistry), vital signs will be listed for Baseline and EOS for each dose level. ECGs will be done at baseline for all participants, and will only be repeated if relevant to an AE.
Changes from Baseline to End of Study laboratory and vital signs will be summarized.
Pharmacokinetic Analysis:
Stool samples will be analyzed for presence of MMB-003 in stool in all participants and summarized using descriptive statistics.

Pharmacodynamic Analysis:
Stool and plasma samples will be analyzed for metabolites for all participants and summarized using descriptive statistics.

Sample Size Justification:
The sample size chosen of 4 participants per cohort (3 active: 1 placebo) is considered to be sufficient for evaluation of safety and tolerability of each cohort. The sample size was not based on statistical power considerations.
This is a Phase 2a study, focused on safety and tolerability. Descriptive statistics will be used to summarize safety, tolerability, pharmacokinetic, and pharmacodynamic data. No formal hypothesis testing.
Missing data will not be imputed.
Sample size justification is based on standard Phase 1 considerations for safety and signal detection in microbiome therapeutic studies.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD
Recruitment hospital [1] 30216 0
Mater Hospital Brisbane - South Brisbane
Recruitment hospital [2] 30321 0
Mater Misericordiae Ltd – QLD - South Brisbane Qld 4101
Recruitment postcode(s) [1] 46610 0
4101 - South Brisbane
Recruitment postcode(s) [2] 46733 0
4101 - South Brisbane Qld 4101

Funding & Sponsors
Funding source category [1] 322990 0
Commercial sector/Industry
Name [1] 322990 0
Melius MicroBiomics Pty Ltd
Country [1] 322990 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Melius MicroBiomics Pty Ltd
Address
Country
Australia
Secondary sponsor category [1] 325941 0
None
Name [1] 325941 0
Address [1] 325941 0
Country [1] 325941 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 321404 0
Bellberry Human Research Ethics Committee D
Ethics committee address [1] 321404 0
Ethics committee country [1] 321404 0
Australia
Date submitted for ethics approval [1] 321404 0
24/06/2026
Approval date [1] 321404 0
08/09/2026
Ethics approval number [1] 321404 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 153606 0
A/Prof Jakob Begun
Address 153606 0
Mater Hospital Brisbane, Mater Misericordiae Ltd Raymond Terrace South Brisbane QLD 4101
Country 153606 0
Australia
Phone 153606 0
+61 731632371
Fax 153606 0
Email 153606 0
Contact person for public queries
Name 153607 0
Sharyn Grossman
Address 153607 0
Mater Hospital Brisbane, Mater Misericordiae Ltd Raymond Terrace South Brisbane QLD 4101
Country 153607 0
Australia
Phone 153607 0
+61 73163 8195
Fax 153607 0
Email 153607 0
Contact person for scientific queries
Name 153608 0
Jakob Begun
Address 153608 0
Mater Hospital Brisbane, Mater Misericordiae Ltd Raymond Terrace South Brisbane QLD 4101
Country 153608 0
Australia
Phone 153608 0
+61 73163 2371
Fax 153608 0
Email 153608 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Regulatory authorities: Information obtained during the research study is subject to inspection for the purpose of verifying the study procedures and data by the relevant authorities (such as the TGA in Australia or the United States of America Food and Drug Administration), authorised representatives of the Sponsor such as study monitors acting on behalf of the Sponsor and its affiliates, representatives, partners, or collaborators, and vendors utilised by the Sponsor for study conduct, the Human Research Ethics Committee (HREC) that reviewed and approved this study, the Institution at which this study is being conducted, or as required by law.

Contract Research Organisation (CRO): Study monitors (people working for or on behalf of the trial Sponsor) to visit the clinical unit to review the clinical trial data so they can verify that study procedures have been followed and the study data have been entered correctly in the study records. This process is called ‘data verification’. This process typically takes place during regular monitoring visits to the Mater Misericordiae Ltd. Monitors are only allowed to view the information for data verification and are not allowed to share your data with other parties. Your medical files are reviewed at the clinical unit for the purposes of the study, your records will be kept secure during this process.

Sponsor/Mater Misericordiae Ltd will share certain information from this study so that others can use it and understand the study findings. This study information does not identify the participant individually.



Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
What individual participant data might be shared?
• All de-identified individual participant data
What types of analyses could be done with individual participant data?
• Any type of analysis (i.e. no restrictions on data re-use)
When can requests for individual participant data be made (start and end dates)?
From:
30/11/2026
To:
No end date
Where can requests to access individual participant data be made, or data be obtained directly?
• Request to be made to Mater Misericordiae Ltd who hold the participant medical records.
Sharyn Grossman +61 7 3163 8195


Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.